SPRY Valuation

ARS Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

13.500

-1.37(-9.213%)1D

Overview
Forecast
Valuation
Earnings

SPRY Relative Valuation

SPRY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SPRY is overvalued; if below, it's undervalued.

Historical Valuation

ARS Pharmaceuticals Inc (SPRY) is now in the Fair zone, suggesting that its current forward PS ratio of 10.15 is considered Fairly compared with the five-year average of -12.06. The fair price of ARS Pharmaceuticals Inc (SPRY) is between 6.04 to 56.90 according to relative valuation methord.

Relative Value

Fair Zone

6.04-56.90

Current Price：14.87

Fair

-10.28

Trailing

Forward

0.00

EV/EBITDA

ARS Pharmaceuticals Inc. (SPRY) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.48. The thresholds are as follows: Strongly Undervalued below -8.88, Undervalued between -8.88 and -5.18, Fairly Valued between 2.22 and -5.18, Overvalued between 2.22 and 5.92, and Strongly Overvalued above 5.92. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-8.48

EV/EBIT

ARS Pharmaceuticals Inc. (SPRY) has a current EV/EBIT of -8.48. The 5-year average EV/EBIT is -7.83. The thresholds are as follows: Strongly Undervalued below -14.86, Undervalued between -14.86 and -11.35, Fairly Valued between -4.32 and -11.35, Overvalued between -4.32 and -0.81, and Strongly Overvalued above -0.81. The current Forward EV/EBIT of -8.48 falls within the Historic Trend Line -Fairly Valued range.

10.75

ARS Pharmaceuticals Inc. (SPRY) has a current PS of 10.75. The 5-year average PS is 6532.11. The thresholds are as follows: Strongly Undervalued below -34825.20, Undervalued between -34825.20 and -14146.54, Fairly Valued between 27210.77 and -14146.54, Overvalued between 27210.77 and 47889.43, and Strongly Overvalued above 47889.43. The current Forward PS of 10.75 falls within the Historic Trend Line -Fairly Valued range.

-14.28

P/OCF

ARS Pharmaceuticals Inc. (SPRY) has a current P/OCF of -14.28. The 5-year average P/OCF is -12.11. The thresholds are as follows: Strongly Undervalued below -27.02, Undervalued between -27.02 and -19.57, Fairly Valued between -4.66 and -19.57, Overvalued between -4.66 and 2.80, and Strongly Overvalued above 2.80. The current Forward P/OCF of -14.28 falls within the Historic Trend Line -Fairly Valued range.

-14.35

P/FCF

ARS Pharmaceuticals Inc. (SPRY) has a current P/FCF of -14.35. The 5-year average P/FCF is -8.09. The thresholds are as follows: Strongly Undervalued below -23.01, Undervalued between -23.01 and -15.55, Fairly Valued between -0.63 and -15.55, Overvalued between -0.63 and 6.83, and Strongly Overvalued above 6.83. The current Forward P/FCF of -14.35 falls within the Historic Trend Line -Fairly Valued range.

ARS Pharmaceuticals Inc (SPRY) has a current Price-to-Book (P/B) ratio of 7.49. Compared to its 3-year average P/B ratio of 3.77 , the current P/B ratio is approximately 98.58% higher. Relative to its 5-year average P/B ratio of 3.77, the current P/B ratio is about 98.58% higher. ARS Pharmaceuticals Inc (SPRY) has a Forward Free Cash Flow (FCF) yield of approximately -3.92%. Compared to its 3-year average FCF yield of -6.11%, the current FCF yield is approximately -35.94% lower. Relative to its 5-year average FCF yield of -6.11% , the current FCF yield is about -35.94% lower.

7.63

P/B

Median3y

3.77

Median5y

3.77

-3.70

FCF Yield

Median3y

-6.11

Median5y

-6.11

Competitors Valuation Multiple

The average P/S ratio for SPRY's competitors is 4.06, providing a benchmark for relative valuation. ARS Pharmaceuticals Inc Corp (SPRY) exhibits a P/S ratio of 10.75, which is 165.03% above the industry average. Given its robust revenue growth of 3043.40%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SPRY.O

ARS Pharmaceuticals Inc

Amphastar Pharmaceuticals Inc

1.87

-4.38%

1.42B

Performance Decomposition

Market capitalization of SPRY increased by 4.01% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 500.00K to 15.72M.

The secondary factor is the Margin Expansion, contributed -88.59%to the performance.

Overall, the performance of SPRY in the past 1 year is driven by Revenue Growth. Which is more sustainable.

3043.40%

500.00K → 15.72M

Revenue Growth

-88.59%

-2.50K → -285.57

Margin Expansion

-2950.80%

1.06 → -30.26

P/E Change

4.01%